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To test the hypothesis that narcolepsy type 1 (NT1) is related to the gut microbiota, we
compared the microbiota bacterial communities of patients with NT1 and control subjects.
Methods
Thirty-five patients with NT1 (51.43% women, mean age 38.29 ± 19.98 years) and 41 controls
(57.14% women, mean age 36.14 ± 12.68 years) were included. Stool samples were collected,
and the fecal microbiota bacterial communities were compared between patients and controls
using the well-standardized 16S rRNA gene amplicon sequencing approach. We studied alpha
and beta diversity and differential abundance analysis between patients and controls, and
between subgroups of patients with NT1.
Results
We found no between-group differences for alpha diversity, but we discovered in NT1 a link
with NT1 disease duration. We highlighted differences in the global bacterial community
structure as assessed by beta diversity metrics even after adjustments for potential confounders
as body mass index (BMI), often increased in NT1. Our results revealed differential abundance
of several operational taxonomic units within Bacteroidetes, Bacteroides, and Flavonifractor
between patients and controls, but not after adjusting for BMI.
Conclusion
We provide evidence of gut microbial community structure alterations in NT1. However,
further larger and longitudinal multiomics studies are required to replicate and elucidate the
relationship between the gut microbiota, immunity dysregulation and NT1.
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Narcolepsy type 1 (NT1) is an orphan disorder characterized
by excessive daytime sleepiness (EDS), cataplexy, hypnagogic
hallucinations, sleep paralysis and disturbed nighttime
sleep.1–3 This sleep disease is associated with psychiatric,
cardiovascular, autonomic and metabolic disorders.3 NT1 is
also called orexin (ORX)/hypocretin deficiency syndrome, as
it is caused by the irreversible loss of ORX neurons in the
lateral hypothalamus.4,5 Patients subsequently need lifelong
management with symptomatic medications.6,7 The precise
underlying process leading to this destruction remains un-
clear; however, several arguments strongly support an auto-
immune origin,8 with the tight association with immune-
related genetic factors, mainly the HLA DQB1*06:02 allele,
the T-cell receptor alpha, and specific adaptative immune
response directed to ORX neurons.9–11 The rarity of familial
cases and the low concordance rate between monozygotic
twins highlight the key role of environmental factors in the
etiology of NT1.6,12 Well-designed environmental studies are
rare in NT1 with low reproducibility, except for the recently
discovered triggers H1N1 influenza infection and vaccination
during the 2009 influenza pandemic.13,14 An association with
Streptococcus pyogenes infections was also reported in NT1,
with high anti-streptolysin O titers when close to disease
onset,8 but it was not replicated in a recent study.15 Although
studies proving causality between environmental factors and
NT1 are rare, it has been hypothesized that infections can
trigger the development of the disease by molecular mimicry
and bystander activation mechanisms.11
The gut microbiota is home to an estimated 100 trillion
bacteria, archaea, fungi and other microbial eukaryotes, as well
as viruses, with the total genome estimated to contain ap-
proximately 3 million genes, 100-fold more than the human
genome.16,17 These organisms have evolved to live in sym-
biosis with their human host. However, the composition of
the gut microbiome has the potential to influence pathogen-
esis of many disorders including neuro(auto)immune diseases
(e.g., MS and neuromyelitis optica spectrum) and neurode-
generative diseases (e.g., Parkinson’s disease, Alzheimer’s
disease, Huntington’s disease) through the microbiota-gut-
brain axis, and more widely, obesity, diabetes, liver diseases
and cancer18,19 A growing body of evidence demonstrates the
complex interactions between the gut microbiota and the
CNS.18–20
Recent advancements with application of high-throughput
sequencing technology (e.g., 16S rRNA gene sequencing21)
allowed to identify many of the unculturable microorganisms
that constitute the human gut microbiota. Differences in
microbiota diversity and relative abundance have been
reported in neuroimmune diseases.18–20 However, whether
gut microbiota dysbiosis is causal or a contributing factor,
involved in onset and/or progression of the disease remains
unclear for most of these disorders.18–20
Assessment of the intestinal microbiome in NT1 is a new field
of investigation. The potential role for gut microbiota in the
pathogenesis of NT1 remains an open question, as well as the
possible, yet hypothetical, presence of a specific microbial
signature. To explore this hypothesis, we compared the fecal
microbiota bacterial communities of well-defined patients
with NT1 and control subjects using a 16S rRNA gene
amplicon sequencing approach.
Methods
Standard protocol approvals, registrations,
and patient consents
This study was approved by the local ethics committees (Comité
de Protection des Personnes, France: Constitution of a cohort
and of a clinical, neurophysiologic and biological bank of rare
hypersomnolence disorders). All adult participants and both
parents for minors provided written informed consent prior to
participation.
Study population
Thirty-five patientswithNT1 (51.43%women,mean age: 38.29±
19.98 years, 5 children >12 y.o.) diagnosed at the National Ref-
erence Center for Narcolepsy, Montpellier, France were recruited
from March 2018 to February 2019. The diagnosis of NT1 was
based on the third International Classification of Sleep Disorders
(ICSD-3) criteria22: presence of EDS for at least 3 months, mean
sleep latency ≤8 minutes on the Multiple Sleep Latency Test
(MSLT), with at least 2 sleep-onset REM periods (SOREMPs),
and typical cataplexy or low CSF levels of ORX-A (<110 pg/mL)
when a lumbar puncture was performed. All patients were positive
for HLA-DQB1*06:02. CSF ORX-A level was determined in 29
(83%) patients in duplicate using the 125I-radioimmunoassay
(RIA) kit from Phoenix Pharmaceuticals, Inc., (Burlingame, CA)
according to the manufacturer’s recommendations. All had low
levels of ORX-A. Patients were systematically evaluated for body
mass index (BMI) (categorized as normal weight [<25 kg/m2],
overweight [25–30 kg/m2], and obese [≥30 kg/m2], and
according to BMI growth curves for children), age at disease onset
and disease duration, and medication intake at time of the study.
None of these patients had significant comorbid psychiatric or
medical disorders.
We also recruited 41 controls (57.14% women, mean age: 36.14
± 12.68 years, 4 children >12 y.o.) during the same period:
Glossary
BMI = body mass index; EDS = excessive daytime sleepiness; IQR = interquartile range; NT1 = Narcolepsy type 1;MSLT =
Multiple Sleep Latency Test; ORX = orexin; OTU = operational taxonomic unit; SOREMP = sleep-onset REM periods.
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18 (44%) were healthy controls selected from the general
population via advertisement and local association networks, and
23 (56%) had an initial EDS complaint, but none of them ful-
filled criteria for a central hypersomnolence disorder (including
narcolepsy). These 23 subjects had no objective sleepiness on
the MSLT (mean sleep latency >8 minutes), no SOREMP, no
abnormalities on nocturnal polysomnography, no complaint of
long sleep time, no medication use, and no other significant
psychiatric, neurologic, or medical disorders.
None of the participants (NT1 and C) were affected with
comorbid neurologic inflammatory or immune pathologies.
None of them were treated with antibiotics, immunotherapy,
or corticosteroids at the time of the study.
Stool sampling
Stool samples were collected for all participants in the sleep
unit from March 2018 to February 2019 using DNA Stool
Collection Tubes containing DNA Stabilizer from the PSP®
Spin Stool DNA Plus Kit of STRATEC Molecular®, and
subsequently frozen and stored at −80°C. Stool samples were
shipped on dry ice to the DNA Sequencing and Genomics
laboratory at the Institute of Biotechnology, University of
Helsinki, Finland for 16S rRNA gene analysis.
DNA extraction
DNA extraction of the samples was performed using the
STRATEC Molecular® PSP Spin Stool DNA Plus Kit
according to the manufacturer’s instructions. Samples were
randomized between extraction batches to minimize batch
effects. Blank extractions were performed from DNA Stabi-
lizer tubes with no addition of template as a way to assess the
presence of possible contaminants.
Library preparation and sequencing
Libraries were obtained by performing 2 steps of PCR. In the
first step the V3-V4 regions of the 16S rRNA gene were am-
plified following a previously published protocol.23,24We used 2
technical replicates (25 μL reactions) per subject sample, and a
mixture of the universal bacterial primers 341F1–4 (59
CCTACGGGNGGCWGCAG 39) and 785R1–4 (59 GAC-
TACHVGGGTATCTAATCC 39) with partial TruSeq adapter
sequences added to the 59 end.23 PCR was done with the fol-
lowing conditions: initial denaturation at 98°C for 30 seconds,
12 cycles at 98°C for 10 seconds, 55°C for 30 seconds, 72°C for
10 seconds, and a final extension at 72°C for 5 minutes. A clean-
up step was performed to remove unused primers and nucle-
otides following a previously published protocol.24 In the sec-
ond PCR step the full-length P5 and P7 Illumina adapters
containing 8 bp indexes (dual-index) were added. The used
indexes were selected using BARCOSEL.25 The two-step PCR
and subsequent quantification, pooling, and purification were
done as described previously.24 The obtained PCR amplicon
pool was checked using Fragment Analyzer (Advanced Ana-
lytical Technologies Inc., Ankeny, IA). PCR of the samples and
the isolation controls were done in batches and every PCR
batch included a blank control (no added DNA template for
amplification) to assess potential contamination. Finally, the
PCR products were sequenced with Illumina MiSeq using the
v3 600 cycle kit paired-end (325 bp + 285 bp). All the samples
were sequenced in a single run to avoid batch effects. The raw
sequence data contained a total of 24,660,868 paired-end reads.
Sequencing data
Primers were removed from the reads using cutadapt (version
2.3)26 with default parameters, an error rate of 10%, minimum
length of overlap between read and adapter set as 3 bp, with
command line provided in supplementary data (Supple-
mentary methods, links.lww.com/NXI/A322). The reads
were paired, quality trimmed, taxonomically classified, and
clustered into operational taxonomic units (OTUs) following
Mothur’s Standard Operating Procedure (SOP) for MiSeq
(Mothur 1.42.1; SOP version last updated on April 4, 2018).27
We inspected the extraction and PCR blanks, which overall
had very low amounts of sequence reads, and since these did
not suggest any overall problems with contamination, we
removed these samples before downstream analysis. The final
sequence data set (without the blanks) consisted of 7,460,575
good quality reads.
Statistical analysis
All statistical comparisons and data visualization were per-
formed with the R statistical programming language
(v. 3.6.1).28 Quantitative variables are presented as mean and
SD, or median with interquartile range (IQR). All p-values are
double-tailed, with statistical significance accepted at an alpha
of 0.05 in alpha and beta diversity, and at an alpha of 0.1 in
differential abundance analysis.
Non-rarefied data without singletons were used for calculating
alpha diversity indices (observed richness, Shannon index and
Inverse Simpson). These 3 different indices were compared
statistically between groups using theWilcoxon rank sum test,
and Spearman’s rank correlation test. Beta diversity, based on
Bray-Curtis dissimilarity, was performed with rarefied data
(37,008 sequences per sample). Beta diversity was visualized
with Non-Metric Multidimensional Scaling and compared
statistically with adonis2 (an implementation of PERMA-
NOVA) from the vegan package.29
Differential abundance analyses were done with DESeq2,30
which uses Generalized Linear Models with a negative binomial
distribution, with Benjamini-Hochberg method for multiple
comparisons correction. A complementary differential abun-
dance analysis was done with ALDEx2,31 which uses a Dirichlet-
multinomial model to infer abundance from counts. Predicted
metagenomic functional potential of the microbial community
was obtained by using PICRUSt2 (v. 2.3.0 beta) (Phylogenetic
Investigation of Communities by Reconstruction of Un-
observed States),32,33 and following the tutorial available on
GitHub. Visualization and statistical comparison of differential
abundances in predicted metagenomic functional potential was
performed using STAMP (v. 2.1.3) (statistical analysis of tax-
onomic and functional profiles)34 and following PICRUSt
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visualization and statistics in STAMP provided in PICRUSt
tutorial. EC (Enzyme Classification) and KEGG (Kyoto En-
cyclopedia of Genes and Genomes) Ortholog pathway pre-
dictions were analyzed after correction formultiple comparisons
(Benjamini-Hochberg FDR).
Data availability
Anonymized data not provided in the article because of space
limitations will be shared by request from any qualified
investigator.
Results
Characteristics of the study population
At the time of the study, the duration of NT1 was 221.5 ± 198.8
months. Thirteen patients (37%) had a normal BMI, 12 (34%)
were overweight and 10 (29%) were obese. At time of study
entry, 26 patients were drug-free while 9 were treated for nar-
colepsy: modafinil (n = 4), methylphenidate (n = 5) alone or in
combination with pitolisant (n = 1), sodium oxybate (n = 1),
venlafaxine (n = 3) and clomipramine (n = 1).
Healthy controls and the control population with a complaint
of EDS did not significantly differ for age, gender and BMI,
and neither in alpha nor beta diversity. Thus, both control
populations were combined to form a single larger control
group. Initial analysis revealed that with respect to micro-
biome compositional data, one control subject was a major
outlier for unknown reasons. We chose to not include this
control subject in subsequent analyses.We found no between-
group differences for age and gender between patients with
NT1 and controls. However, BMI was higher in patients
than controls (median [IQR]: 26.2 [23.3–30.3] vs 23.1
[20.6–24.2], p < 0.001).
Alpha diversity
Alpha diversity defined as microbial community richness and
evenness did not differ between patients with NT1 and con-
trols as assessed with the Shannon (Wilcoxon rank sum test:
p = 0.07814, W = 887) and Inverse Simpson (Wilcoxon rank
sum test: p = 0.06801, W = 893) indices, nor with observed
richness (Wilcoxon rank sum test: p = 0.1281, W = 864).
Alpha diversity was also investigated as function of age, gender
and BMI, with no significant effects found (Supplementary
table 1, links.lww.com/NXI/A321).
We further analyzed in patients with NT1 the association be-
tween alpha diversity and demographic and clinical character-
istics such as gender, age, disease duration, BMI, and
medication (Supplementary table 2, links.lww.com/NXI/
A321). We found no associations except between the Shannon
index (i.e., a commonly used index to characterize diversity in
terms of richness and evenness) and disease duration (Spear-
man’s rank correlation test: p = 0.038, r = 0.352).
Beta diversity
Beta diversity quantifies the community composition dissimilarity
between samples and showed significant differences between
patients and controls using Bray-Curtis dissimilarity in univariable
PERMANOVA models (p = 0.026, R2 = 0.023) (figure 1). We
also found trends for dissimilarity for gender (p = 0.0549, R2 =
0.02) and BMI (p = 0.082, R2 = 0.019), but not for age, disease
duration and medication. The difference between patients and
controls remained significant after adjustment for gender and
BMI in a multivariable model (Diagnosis: p = 0.027, R2 = 0.023;
Gender: p = 0.032, R2 = 0.022; BMI: p = 0.055, R2 = 0.02).
We further analyzed the Beta diversity in patients with NT1 in
univariablemodels as a function of gender, age, disease duration,
BMI, and medication, but found no significant associations.
Differential microbial abundance analyses
between patients with NT1 and controls
The data set was composed of 7,243 non-singleton OTUs
distributed into 180 genera, 73 families, 36 orders, 22 classes
and 12 phyla. The 20 most common and the 5 most abundant
genera (e.g., Bacteroides, Faecalibacterium, Roseburia, Pre-
votella, and Ruminococcus) in patients and controls are shown
in figure 2. We analyzed the differential abundance at different
taxonomic levels, namely OTU, genus, family, and phylum
levels with DESeq2. For every taxon level, we identified and
plotted the normalized counts and the relative abundances of
Figure 1 NMDS ordination plot of the control (C) and nar-
colepsy (NT1) samples
Ordination based on Bray-Curtis dissimilarity calculated with genus-level
data, randomly rarefied to 37,008 sequences per sample. Ellipses indicate
95% confidence intervals. Each point represents one sample. The closer the
points are to one another, themore similar themicrobiome compositions of
the samples are. NMDS = Non-Metric Multidimensional Scaling; NT1 = Nar-
colepsy type 1.
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the significant differentially abundant taxa if any, the 20 most
common taxa, as well as the 20 taxa with the lowest corrected
p-value for multiple comparisons. We found several taxa with
differential abundance between patients with NT1 and con-
trols (table 1 and figure 3). BacteroidesOtu00012 and Bacteria
unclassified Otu00078 were decreased in NT1 compared to
controls, while Flavonifractor Otu00099 and Bacteroidetes
unclassified Otu00102 were increased in NT1 compared to
controls. After adjusting for gender, 3 among the 4 taxa
remained significant between groups: Bacteroides Otu00012,
Bacteria unclassified Otu00078 and Flavonifractor Otu00099.
However, after correction for BMI alone, and then gender and
BMI in the same model, no taxa remained statistically sig-
nificant for differential abundance between groups. Few other
between-group differences were identified at OTU, genus,
family and phylum taxonomic levels. However, a detailed
review of the normalized counts plots and the relative abun-
dance plots showed several outliers in both groups and
thereafter these taxa could no longer be considered as dif-
ferent between the groups.
A complementary differential abundance analysis was done
with ALDEx2 at all taxonomic levels; however we found no
significant differences between groups in any of the compar-
isons performed.
Relative microbial abundance analyses
according to demographic and clinical
characteristics in patients with NT1
We analyzed the differential abundance analysis at genus level
within patients with NT1 according to age (in children
compared to adults), disease duration (population divided as
the median of disease duration, adjusted only for age), BMI
(population divided into obese, non-obese), and medication
(in untreated and then in treated patients). Among these
subgroups, DESeq2 identified the following taxa as differen-
tially abundant (Age: Acidaminococcus, Allisonella, Alloprevo-
tella, Catenibacterium, Holdemanella, Klebsiella, Prevotella;
disease duration: Alloprevotella, Butyrivibrio; BMI: Alloprevo-
tella, Clostridium IV, Coprobacillus, Intestinimonas,Mitsuokella;
medication: Faecalicoccus, Klebsiella, Parasutterella, Veillo-
nella). However, the sample size of the different subgroups
was small, and the review of the normalized counts and the
relative abundance plots showing the presence of outliers
suggested that the significant differences were rather statistical
noise than true between-group differences.
Figure 2 The most 20 common genera between patients with NT1 and controls
Mean relative abundance of 20 most common
genera organized as control (C) and patient (NT1)
groups. NT1 = Narcolepsy type 1.
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Predicted metabolic pathways
PICRUSt2’s predictions of microbial metabolic pathway
abundances were used to infer potential differences between
patients with NT1 and controls. We found no significant dif-
ferences in predicted metabolic function patterns between
patients with NT1 and controls.
Discussion
Here, we report an assessment of gut microbiota diversities and
relative abundances in a well-characterized population of patients
with NT1 compared with control subjects. We found no between-
group differences for alpha diversity that quantifies both taxonomic
richness and evenness, except for the Shannon index that corre-
lated with NT1 disease duration. This result suggests that richness
and evenness ofmicrobial speciesmay differ as a functionof disease
evolution in patients with NT1. We also reported a significant
difference regarding the global bacterial community structure in
NT1 vs controls, as assessed by beta diversitymetrics. These results
highlighted that the microbial community differs between patients
withNT1 and controls, even after adjustment for BMI.We further
explored with the DESeq2 analyses whether the community dif-
ferences between groups are driven by changes in the abundance of
certain taxa. Few microbial species were differentially abundant
between patients and controls with one OTU among Bacteroides
and one OTU among unclassified bacteria, which were decreased
in patients, whereas anOTUamong unclassifiedBacteroidetes and
one OTU among Flavonifractor were increased in patients with
NT1 compared with controls. After adjustment for BMI, these
differences did not remain significant and thus may not be asso-
ciated with NT1 per se. Importantly, metabolic disturbances such
as overweight/obesity are frequently associated with NT1: one-
third of adults with NT1 are obese, and 50% of children, with a
rapid weight increase close to disease onset.3,35,36
Several studies have attempted to define what constitutes an
“obese” vs a “healthy” gut microbiota.37,38 Generally, microbial
diversity is an essential component to host health, and obese
individuals have a lower bacterial diversity and decreased fecal
microbial richness.39 The question whether changes in beta di-
versity and subtle differential community abundance between
patients withNT1 and controls were directly related to the disease
per se or to confounders such as BMIneeds to be further explored.
Our global resultsmay argue for a shift of the whole community
structure in patients with NT1 compared with controls. Using
the DESeq2 analyses, we found that the community differences
between groups may relate to changes in abundance of few
taxa; however, a complementary abundance analysis performed
with the ALDEx2 at all taxon levels, found no between-group
statistically significant results. ALDEx2 is a very conservative
method, and it is not uncommon that results detected by
DESeq2 or other methods are not reproduced by ALDEx2.23
The analysis of predicted metabolic pathways did not reveal
functional differences between groups that would reflect the
observed compositional differences. Finally, we did not find any
association between microbial community structure and de-
mographic and clinical characteristics in patients with NT1.
Although preliminary, the gut microbial diversity alteration we
found here in NT1 reinforces the hypothesis of the important
role of the environment in NT1 development and pathogenesis.
It is now widely accepted by the scientific community that the










All C and all
NT1
Diagnosis OTU Bacteroides Otu00012 1,058.259 +13.999 in C 8.66e-16
All C and all
NT1
Diagnosis OTU Bacteria unclassified
Otu00078
109.098 +8.144 in C 3.18e-04
All C and all
NT1
Diagnosis OTU Flavonifractor Otu00099 91.947 +1.697 in NT1 1.64e-02
All C and all
NT1
Diagnosis OTU Bacteroidetes unclassified
Otu00102
62.685 +10.048 in NT1 2.10e-02




OTU Bacteroides Otu00012 1,058.259 +13.94 in C 3.78e-16






173.435010 +8.01 in C 1.66e-04




OTU Flavonifractor Otu00099 91.946991 +1.6376 in NT1 5.10e-03
Abbreviations: C = controls; NT1 = narcolepsy type 1; OTU = operational taxonomic unit.
Variation of the significantly differentially abundant taxa without correction and after correction for gender. Log2FoldChange: estimation of the effect size (as
a fold change) in log 2 scale and orientation of the variation; it represents howmuch does the abundance of the taxumof interest changes between groups (C
and NT1). It also gives the orientation of this change.
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immune system is involved in the death of ORX neurons.3,40
Complex interactions have been established between the gut
microbiota and the CNS, and gut-brain interactions may occur
through immune-mediated inflammatory pathways.18,19 The
gutmicrobiota plays a key role inmaintaining the integrity of the
intestinal epithelium and the mucosal barrier.39 Several other
Figure 3 Normalized counts and relative abundance plots between patients with NT1 and controls
Visualization of differential abundance with plot of normalized counts and relative abundances of bacterial OTUs in the control (C) and narcolepsy (NT1)
groups. Lower and upper hinge of the box: 1st and 3rd quartile; line: median; red diamond: mean. Three OTUs are represented: Bacteroides Otu00012,
Bacteria unclassifiedOtu00078, and FlavonifractorOtu00099—the significantly differentially abundant OTUs (DESeq2 p < 0.1) between control andNT1 groups
after adjusting for gender. NT1 = Narcolepsy type 1; OTU = operational taxonomic unit.
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roles of the gut microbiota were highlighted with modulation of
CNS inflammation, regulatory cells from both T and B cell
lineages, and changes in cytokine activities and microglia acti-
vation, all potential players involved in the pathogenesis of
NT1.18,19,41–43 Hence, subtle changes in the microbiome may
modulate risk of NT1 in genetically predisposed individuals
(carrying the HLA DQB1*06:02 allele) as already reported in
several neuro(auto)immune disorders such as MS.18,44
At this point, it remains unclear whether the changes in the
gut microbiota are robust in NT1 and whether these changes,
if confirmed, are involved in disease causation or are rather a
consequence of the disease. Regarding the latter, it also can-
not be ruled out that latent identified (such as BMI) or un-
identified clinical confounders are involved, meaning that
observed beta diversity and taxon abundance differences may
not even be a consequence of the disease state itself. In ad-
dition, how microbiota affect changes in (auto)immunity re-
lated to NT1, symptom burden, disease progression, and drug
treatment responses remains to be further established.
Whether the modulation of the microbiome can lead to either
exacerbation or improvement of symptoms in NT1, especially
close to disease onset, remains also to be investigated.
This study has several strengths and limitations. We included
well-characterized patients with NT1 comparable with control
subjects about gender and age, with recruitment of subjects
within the same geographical region and from the same period.
None of the participants had comorbid immune diseases, an
expected condition in NT1; this disorder having a unique
pathophysiology.45 Experimental design with standardized col-
lection and storage; molecular analysis technology and methods
for data analysis were performed according to the best practice
methods, with strong precautions to minimize batch effects and
contamination.46,47 The main limitation of our study is the small
sample size. However, NT1 affects only 1 in 2,000 people
worldwide, so the rarity of this sleep disorder justifies the present
report of the first small-scale exploratory study of the gut
microbiota in NT1. Unfortunately, owing to heavily tailed zero-
inflated distributions of bacterial abundances and the multivari-
ate nature of the data, power calculations for microbiome studies
are challenging, and no consensus exist on how they should be
conducted. The question of whether the difference in beta di-
versity and subtle changes in relative abundance of microbial taxa
between narcolepsy and control samples reflects an underlying
diversity or sampling bias remains to be confirmed. Patients with
NT1 had a higher BMI than control subjects, which may have
introduced bias into the analysis despite our model adjustments.
In addition, our study lacks assessments of lifestyle, diet as well as
gastrointestinal discomfort in our subjects, and questionnaires on
gut and on depressive symptoms, which would have further
improved confounder adjustment. Indeed, a recent study
reported a large spectrum of clinical autonomic dysfunction in
NT1 with impairment in the gastrointestinal area that may
modify the gut microbial composition.48 Moreover, most of the
patients were recruited long after disease onset, but long delays
between symptoms onset and diagnosis remain unfortunately
the rule for this rare disease.49 Therefore, possible transitory
microbiota alterations, more pronounced during the autoim-
mune processes at disease initiation, may have become un-
detectable during the follow-up period. Owing to the lack of
power in the analysis of subgroups of patients based on clinical
characteristics, we cannot at this stage discern the effects of
endophenotypes, comorbidities, and of medications taken by
patients with NT1 on abundances in the microbial community.
Finally, our results cannot be considered as definite identification
of specific gutmicrobial community structure alterations inNT1.
We need larger sample sizes in the future to obtain more reliable
estimates, and different study designs with longitudinal studies
and randomized controlled trials withmultiple time points of the
same subjects to elucidate potential causal relationships and to
find out if targeting the microbiome can yield novel therapeutic
strategies.
To conclude, we provide evidence for differences in gut mi-
crobial communities in NT1. However, our preliminary results
cannot be considered a definite identification of specific
microbiome-based biomarkers in narcolepsy. Further larger,
and preferably longitudinal, multiomics studies are required to
replicate our findings, to elucidate the relationship between the
gut microbiota and NT1, and to determine the role of the
microbiome in the development of the disease, if any.
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21. Böttger EC. Rapid determination of bacterial ribosomal RNA sequences by direct
sequencing of enzymatically amplified DNA. FEMSMicrobiol Lett 1989;53:171–176.
22. AASM: American Academy of SleepMedicine. ICSD-3: International Classification of
Sleep Disorders, 3rd ed. Chest 2014;146:1387–1394.
23. Aho VTE, Pereira PAB, Voutilainen S, et al. Gut microbiota in Parkinson’s disease:
temporal stability and relations to disease progression. EBioMedicine 2019;44:691–707.
24. Pereira PAB, Aho VTE, Paulin L, Pekkonen E, Auvinen P, Scheperjans F. Oral and
nasal microbiota in Parkinson’s disease. Parkinsonism Relat Disord 2017;38:61–67.
25. Somervuo P, Koskinen P, Mei P, Holm L, Auvinen P, Paulin L. BARCOSEL: a tool for
selecting an optimal barcode set for high-throughput sequencing. BMC Bio-
informatics 2018;19:257.
26. Martin M. Cutadapt removes adapter sequences from high-throughput sequencing
reads. EMBnet J 2011;17:10–12.
27. Kozich JJ, Westcott SL, Baxter NT, Highlander SK, Schloss PD. Development of a dual-
index sequencing strategy and curation pipeline for analyzing amplicon sequence data on
the MiSeq Illumina sequencing platform. Appl Environ Microbiol 2013;79:5112–5120.
28. R Core Team, 2020. R: A language and environment for statistical computing. R
Foundation for Statistical Computing, Vienna, Austria. Available at: URL https://
www.R-project.org/.
29. Oksanen J, Blanchet F G, Friendly M, et al., 2019. Vegan: Community Ecology
Package. R package version 2.5-6. Available at: https://CRAN.R-project.org/
package=vegan.
30. LoveMI, HuberW, Anders S. Moderated estimation of fold change and dispersion for
RNA-seq data with DESeq2. Genome Biol 2014;15:550.
31. Fernandes AD, Macklaim JM, Linn TG, Reid G, Gloor GB. ANOVA-like differential
gene expression analysis of single-organism and meta-RNA-seq. PLoS one 2013;8:
e67019.
32. Langille MGI, Zaneveld J, Caporaso JG, et al. Predictive functional profiling of mi-
crobial communities using 16S rRNA marker gene sequences. Nat Biotechnol 2013;
31:814–821.
33. Douglas GM, Maffei VJ, Zaneveld J, et al. PICRUSt2: an improved and extensible
approach for metagenome inference. BioRxiv 2019:672295.
34. Parks DH, Tyson GW, Hugenholtz P, Beiko RG. STAMP: statistical analysis of
taxonomic and functional profiles. Bioinformatics 2014;30:3123–3124.
35. Inocente CO, Lavault S, Lecendreux M, et al. Impact of obesity in children with
narcolepsy. CNS Neurosci Ther 2013;19:521–528.
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